Replimune (REPL) Net Income towards Common Stockholders (2017 - 2026)
Replimune (REPL) reported Net Income towards Common Stockholders of -$73.2 million for Q1 2026, up 1.23% on a YoY basis from -$72.3 million in Q1 2025, and down 3.22% sequentially from -$70.9 million in Q4 2025.
Replimune (REPL) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Replimune (REPL) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$73.2 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 1.23% year-over-year to -$73.2 million; the trailing twelve-month figure through Mar 2026 stood at -$313.9 million (down 26.95% YoY), and the FY2026 full-year result was -$313.9 million, down 26.95% from the prior year.
- Net Income towards Common Stockholders slipped to -$73.2 million in Q1 2026, from -$70.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$31.7 million in Q1 2022 to a low of -$86.7 million in Q2 2025.
- A 5-year average of -$57.8 million and a median of -$53.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders advanced 11.64% in 2024 and sank 61.22% in 2025, its largest moves.
- Tracing REPL's Net Income towards Common Stockholders over 5 years: stood at -$39.7 million in 2022, then slipped by 28.8% to -$51.1 million in 2023, then decreased by 29.77% to -$66.3 million in 2024, then fell by 6.92% to -$70.9 million in 2025, then decreased by 3.22% to -$73.2 million in 2026.
- Business Quant data shows REPL's Net Income towards Common Stockholders at -$73.2 million in Q1 2026, -$70.9 million in Q4 2025, and -$83.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -0.68 |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | -73.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.22 Mn |
| Dec 31, 2025 | -70.93 Mn |
| Sep 30, 2025 | -83.10 Mn |
| Jun 30, 2025 | -86.69 Mn |
| Mar 31, 2025 | -74.13 Mn |
| Dec 31, 2024 | -66.34 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.08 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.24 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.70 Mn |
| Dec 31, 2021 | -29.67 Mn |
| Sep 30, 2021 | -29.36 Mn |
| Jun 30, 2021 | -27.31 Mn |